Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 485 • 2016 ACR/ARHP Annual Meeting
Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Emily Wu¹, Richard Bell², Christopher Rudmann³, Ronald Wood⁴, Christopher T. Ritchlin⁵, Homaira Rahimi⁶ and Edward Schwarz⁷, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, ⁴University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁷Orthopedeatrics, University of Rochester, Rochester, NY
Background/Purpose: Although rheumatoid arthritis (RA) tends to occur earlier and with increased severity in females, the underling etiology of this sexual dimorphism is unknown. We…
Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Frank H.J. van den Hoogen^1,2, Jaap Fransen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Aatke van der Maas¹ and Noortje van Herwaarden¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…
Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Josef Smolen¹, Roy Fleischmann², Daniel Aletaha³, Yihan Li⁴, Stefan Florentinus⁴ and Ivan Lagunes Galindo⁴, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Medical University Vienna and Hietzing Hospital, Vienna, Austria, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…
Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Sheng-Xiao Zhang¹, Miao Miao², Xiao-Qing Liu², Xiao-Wen Ma², Xiao-Yan Wu² and Xiao-Feng Li¹, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting
Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients
Fadil Pirbuccus¹, Christine Galant¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez² and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
Abstract Number: 3124 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene
Teresina Laragione¹, Percio Gulko¹ and Max Brenner², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but…
Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Paul-Peter Tak^1,2,3, Marieke E. Doorenspleet⁴, Maria de Hair⁵, Paul L. Klarenbeek⁶, Marian van Beers-Tas⁷, Antoine H.C. van Kampen⁸, Dirkjan van Schaardenburg^9,10, Danielle M. Gerlag^11,12, Frank Baas¹³ and Niek de Vries¹⁴, ¹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ³currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, ⁴Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, ⁸Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ⁹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹¹Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ¹²Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, ¹³Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ¹⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…
Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 1111 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Receptor Tyrosine Kinases Mediated Activity and Cell Invasiness in Fibroblast-like Synoviocytes
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is a new arthritis severity gene recently identified in the Pristane and Collagen-induced arthritis (PIA, CIA) quantitative trait locus Cia25/Pia42…
Abstract Number: 1435 • 2016 ACR/ARHP Annual Meeting
KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Mark Tanner¹, Redwan Huq¹, Rajeev Tajhya¹, Michael Pennington², Teresina Laragione³, Pércio Gulko⁴ and Christine Beeton⁵, ¹Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, ²Peptides International, Louisville, KY, ³Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibroblast-like synoviocytes (FLS) develop a high degree of invasiveness during rheumatoid arthritis (RA), leading to joint degradation. There are currently no therapeutics that specifically…
Abstract Number: 1436 • 2016 ACR/ARHP Annual Meeting
TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Hiroaki Hayashi, Takafumi Harada, Shunsuke Demizu, Fumito Tatsuzawa, Ken Sato, Morihiro Mitsuya, Kenji Tanaka, Kazuhiko Yonekura, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The family of Janus kinases (JAKs) plays important roles in signaling pathway mediated by various cytokine receptors. An aberrant activation of JAK-STAT signaling…
Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1451 • 2016 ACR/ARHP Annual Meeting
Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis
Soshi Takahashi¹, Jun Saegusa², Ikuko Naka³, Kosaku Tsuda³, Takaichi Okano⁴, Kengo Akashi³, Sho Sendo², Yo Ueda³, Akira Onishi⁵, Yoshinori Kogata² and Akio Morinobu², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Many signaling pathways activated under inflammatory and hypoxic conditions have profound effects on intracellular metabolism to support cell growth and survival. Cancer cells consume…
Abstract Number: 1462 • 2016 ACR/ARHP Annual Meeting
Magnesium Is a New Mediator Arthritis Severity and Joint Damage
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Given the effects of magnesium supplementation in suppressing components of the innate immunity in short-term studies, we examined the effect of dietary magnesium modifications…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].